Business Context and Reporting Period
This Form 8-K Current Report was filed by Supernus Pharmaceuticals, Inc. on August 21, 2014. The filing addresses a specific legal event regarding the company's intellectual property portfolio rather than a standard financial reporting period.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a regulatory and legal event.
Material Changes
On August 21, 2014, Supernus received a Paragraph IV Notice Letter from Actavis Laboratories FL, Inc. This notice indicates that Actavis has filed an Abbreviated New Drug Application (ANDA) seeking approval for generic topiramate extended-release capsules. This represents a potential challenge to Supernus's market exclusivity for its product, Trokendi XR.
Outlook, Risks, and Management Commentary
- Management Response: Supernus is reviewing the Notice Letter and intends to vigorously enforce its intellectual property rights.
- Patent Protection: Trokendi XR is currently protected by three issued patents listed in the FDA's Orange Book.
- Expiration Dates: These patents expire no earlier than 2027.
- Risk: The filing of the ANDA by a generic competitor poses a risk to future revenue streams if the patents are successfully challenged or invalidated.
Investor Verification Checklist
- Verify the specific claims made in Actavis's Paragraph IV Notice Letter regarding the validity of Supernus's patents.
- Monitor the status of the three patents protecting Trokendi XR listed in the FDA Orange Book.
- Review the full text of the press release (Exhibit 99.1) for additional details on the legal strategy.
- Assess the potential impact of generic competition on the projected sales of Trokendi XR post-2027.